Lonza divests peptide business in Belgium to PolyPeptide Group

The facility has around 280 employees.

Lonza and PolyPeptide group jointly announced that they both entered defiitive agreement for Polypeptide Laboratories Holding to acquire the peptides business and operations of Lonza in Braine-l’Alleud, Belgium.

Lonza's Braine facility has approximately 280 employees and is the center of peptide chemical development and manufacturing within Lonza.

The acquisition is said to enhance PolyPeptide’s manufacturing capacity and capabilities and will enable
seamless support for its broad portfolio as many products progress toward regulatory approval and
commercial supply.

PolyPeptide group CEO Jane Salik said the addition of Lonza’s Braine facility to PolyPeptide is a great fit and will offer its customers an even more comprehensive range of services for every stage of development.

“With this acquisition we will be expanding our capacity to meet the needs of customers who demand the highest quality products with the most robust, scalable and costefficient peptide manufacturing processes at every scale,” she said.